I

India Globalization Capital
D

IGC

0.38800
USD
0.00
(0.26%)
Market Closed
Volume
1,400
EPS
0
Div Yield
0
P/E
-2
Market Cap
29,346,931
OverviewSignalsIdeasNews
Related Instruments
    A
    ACB
    -0.08000
    (-1.30%)
    6.06000 USD
    C
    CGC
    -0.82500
    (-10.86%)
    6.77500 USD
    C
    CRON
    -0.11000
    (-4.49%)
    2.34000 USD
    H
    HEXO
    -0.03000
    (-2.36%)
    1.23000 USD
    O
    OGI
    -0.12000
    (-7.14%)
    1.56000 USD
    S
    SNDL
    -0.07000
    (-3.08%)
    2.20000 USD
    T
    TLRY
    -0.03500
    (-1.73%)
    1.98500 USD
    V
    VFF
    -0.04000
    (-3.54%)
    1.09000 USD
    More
News

Title: IGC Pharma

Sector: Healthcare
Industry: Biotechnology
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.